HIV Infections Clinical Trial
Official title:
Planned Parenthood Center of El Paso Adopting and Demonstrating the Adaptation of Prevention Techniques With Popular Opinion Leader (ADAPT-POL)
This study will look at the following questions:
- Was there a significant difference in HIV prevention knowledge, risk reduction
attitudes, norms, intentions, self efficacy, number of sexual partners, and incidence
of unprotected anal intercourse among seropositive Hispanic men who have sex with men
(MSM) after the implementation of ADAPT-POL?
Hypothesis: There will be a significant increase in HIV prevention knowledge, intentions,
and self efficacy concerning condom use. There will be a decrease in risk attitudes, norms,
number of sexual partners, and incidence of unprotected anal intercourse among seropositive
Hispanic MSM after the implementation of ADAPT-POL.
- How is exposure to the intervention and intervention dosage related to the following
variables: HIV prevention knowledge, attitudes, intentions, and behaviors concerning
unprotected anal intercourse?
Hypothesis: Intervention exposure and dosage are positively correlated with improved HIV
prevention knowledge, attitudes, intentions, and behaviors concerning unprotected anal
intercourse.
The proposed project, Adopting and Demonstrating the Adaptation of Prevention Techniques
(ADAPT), has two main goals: first, to assist the Centers for Disease Control and Prevention
(CDC) to better understand the processes needed for adapting evidence-based behavioral
interventions to fit new conditions or target populations; second, to utilize the CDC's
draft adaptation guidance to adapt Jeff Kelly's Popular Opinion Leader (POL) for use with
adult, seropositive Hispanic men who have sex with other men (MSM). The target population
will directly participate in all phases of the intervention adaptation process.
ADAPT, known as ADAPT-POL in El Paso, will include formative research and outcome
monitoring. Throughout both periods, the ADAPT-POL staff will conduct process monitoring and
evaluation to assess the delivery of the intervention, and to help the CDC understand how
the draft adaptation guidance procedures work in a real world setting. Representatives of
the target population will participate in focus groups, key informant interviews, and
community advisor meetings during the formative phase; and potentially serve as popular
opinion leaders (POLs) during the implementation phase.
The knowledge obtained during the ADAPT-POL intervention will be diffused to other
interventions and programs at the Planned Parenthood Center of El Paso (PPCEP). This will
allow PPCEP management and staff to make informed decisions about the adoption of
interventions and what steps might be necessary to adapt existing and future PPCEP
interventions that target Hispanic populations. At the conclusion of ADAPT activities, the
CDC-developed draft adaptation guidance will be revised based on lessons learned.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |